LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

2.73 -3.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.5300000000000002

Maxim

2.83

Indicatori cheie
By Trading Economics
Venit	1.2M -31M
Vânzări	-70K 1.3M
EPS	-0.26
Marjă de profit	-2,402.848
Angajați	161
EBITDA	12M -30M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+68.31% upside

Dividende
By Dow Jones
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	8.8M 262M
Deschiderea anterioară	6.26
Închiderea anterioară	2.73

Sentimentul știrilor

By Acuity

84%

16%

318 / 344 Clasament în Healthcare

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 iun. 2026, 23:38 UTC

Achiziții, Fuziuni, Preluări

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 iun. 2026, 22:08 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 iun. 2026, 21:55 UTC

Achiziții, Fuziuni, Preluări

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 iun. 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 iun. 2026, 21:22 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 iun. 2026, 20:46 UTC

Achiziții, Fuziuni, Preluări

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 iun. 2026, 20:22 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares $11 Special Div

1 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 iun. 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 iun. 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 iun. 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 iun. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 iun. 2026, 18:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 iun. 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 iun. 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 iun. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 iun. 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 iun. 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 17:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

68.31% sus

Prognoză pe 12 luni

Medie 4.78 USD 68.31%

Maxim 7 USD

Minim 2.2 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

318 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.